Lung Cancer Europe shared a post on LinkedIn:
“MET has long been known to play a role in some lung cancers, particularly through MET gene changes such as exon 14 skipping or amplification.
What newer research is adding is a clearer focus on MET overexpression – when cancer cells produce high levels of the MET protein, even without a clear gene change. This is becoming important as new treatments are being developed that target high MET expression, not just MET mutations.
Understanding these differences helps explain why MET may be checked at diagnosis, or again later if treatment stops working.
Source (new research):
Nature, npj Precision Oncology (2025) – review on MET overexpression in NSCLC.”
Title: MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer
Authors: Ming-Sound Tsao, Lynette Sholl, Michelle Shiller, Peter Illei, Ignacio I. Wistuba, Mary Beth Beasley, Kurt A. Schalper, Archana Simmons, Peter Ansell, Sue Beruti, Mari Mino-Kenudson
Read the Full Article.
More posts featuring Lung Cancer Europe on OncoDaily.